2025 Annual Meeting | Industry Therapeutic Update from UCB: Rethinking Seizure Emergencies

2025 Annual Meeting | Industry Therapeutic Update from UCB: Rethinking Seizure Emergencies—Expert Perspectives on a New Paradigm

Date Monday 04/07/25

Time 06:00 PM - 08:00 PM PDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Kamil Detyniecki, MD, Sheryl R. Haut, MD

Topic(s) Epilepsy/Clinical Neurophysiology (EEG), General Neurology

Learning Objectives How do you define a ‘seizure emergency’? When should a rescue medication be used? What is the impact of route of administration on time to onset of effect? These are just a few of the questions that will be asked in this audience participation event where we will want to hear from you and your peers. In this session, experts will discuss the latest thinking and developments around seizure emergencies, including a new paradigm for rapid and early seizure termination (REST) and acute cluster termination (ACT).

Objectives
This program will aim to meet the following objectives:
• Discuss the burden of seizure emergencies and importance of seizure action plans in all phases of life
• Describe the recent consensus recommendations around defining seizure emergencies, including prolonged seizures and seizure clusters
• Examine the available treatment options for terminating a seizure emergency

This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
06:00 PM - 08:00 PM PDT	Speaker	Industry Therapeutic Update from UCB: Rethinking Seizure Emergencies—Expert Perspectives on a New Paradigm”.

Faculty Disclosures
Kamil Detyniecki, MD	Dr. Detyniecki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aquestive. Dr. Detyniecki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Detyniecki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Detyniecki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwich.
Sheryl R. Haut, MD	Dr. Haut has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ventus. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbieVe. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Iqvia.

��ɫ��

��ɫ��